

# Role of DEAD box 1 in retinoblastoma and neuroblastoma

Roseline Godbout<sup>†</sup>,  
Lei Li, Rong-Zong Liu &  
Ken Roy

<sup>†</sup>Author for correspondence  
Cross Cancer Institute, 11560  
University Avenue,  
Edmonton, Alberta  
T6G 1Z2 Canada  
Tel.: +1 780 432 8901;  
Fax: +1 780 432 8892;  
roseline@cancerboard.ab.ca

Analysis of hereditary and nonhereditary retinoblastoma led to the formulation of the two-hit hypothesis of cancer in the early 1970s. The two-hit hypothesis was validated in the 1980s when both copies of the *RB1* gene were shown to be mutated in hereditary and nonhereditary retinoblastoma. However, consistent genetic abnormalities other than *RB1* mutations suggest that additional events may be required for the formation of these malignant tumors. For example, *MYCN* amplification has long been known to occur in both retinoblastoma and neuroblastoma tumors and is strongly associated with poor prognosis in neuroblastoma. The DEAD box gene, DEAD box 1 (*DDX1*), is often coamplified with *MYCN* in both these childhood tumors. Here, we examine possible roles for *DDX1* overexpression in retinoblastoma and neuroblastoma.

## DEAD box proteins

DEAD box genes encode a family of putative RNA helicases (ATP-dependent RNA unwinding proteins) whose primary role is to alter the secondary structure of RNA molecules. DEAD box proteins share nine conserved domains (Q, I, Ia, Ib, II–VI) [1,2] with roles in ATP binding/hydrolysis, RNA binding and RNA unwinding. The signature domain (motif II) of DEAD box proteins, D(asp)-E(glu)-A(ala)-D(asp), is involved in ATP binding/hydrolysis and the coupling of ATPase and RNA unwinding activities (Figure 1). Motifs I and VI contain ATP-binding sites, whereas motif III may link ATP hydrolysis with helicase activity, and motif Q has been postulated to regulate ATP binding and hydrolysis. Motifs Ia, Ib, IV and V are believed to play roles in RNA binding and unwinding [3,4].

DEAD box proteins are found in most organisms, from complex multicellular plants and animals to bacteria and viruses. A total of 36 DEAD box proteins have been identified in the human genome [5]. Related to the DEAD box proteins are the DEAH proteins, which appear to be primarily involved in RNA splicing, and the DExH proteins. DEAD/DEAH/DExH proteins are all part of the helicase superfamily 2 [6], and are generally thought to have little processive activity, acting more like clamps to prevent RNAs from reassociating [7]. The only member of this family shown to have processive activity is the DExH protein NPH-II from *Vaccinia virus* [8]. NPH-II can unwind up to 83 bp of dsRNA at a rate of 6 bp per kinetic step.

One of the best-characterized eukaryotic DEAD box proteins is the translation initiation factor eIF-4A (DDX2). eIF-4A binds nucleic

acids and unwinds RNA–RNA and RNA–DNA duplexes in an ATP-dependent manner, and has RNA-dependent ATP hydrolysis activity [9,10]. eIF-4A is believed to be a nonprocessive or slightly processive RNA helicase whose activity is enhanced in the presence of other proteins, such as eIF-4B and eIF-4G, especially in the presence of extensive RNA secondary structure [11–14]. Proposed biochemical functions for eIF-4A include:


- Unwinding the 5' ends of mRNAs to facilitate translation;
- Motor activity, whereby the eIF-4A/ribosome is used to translocate mRNA as ATP is hydrolysed;
- Alteration of RNA structure to either facilitate or inhibit the binding of translational factors and other factors [10].

Other DEAD box proteins with RNA unwinding activity, RNA-dependent ATPase activity, and the ability to unwind/destabilize RNA, include p68 (DDX5), *Drosophila* vasa (DDX4), *Xenopus* An3 (DDX3), human p54 (DDX6) and yeast Dbp5p (DDX19) [15–20]. Despite considerable interest in this protein family, the biological role of the majority of DEAD box proteins remains poorly understood. DEAD box proteins have been proposed to serve as multifunctional RNA chaperones that promote the formation of particular RNA structures and transport RNAs from one compartment of the cell to another [21]. For example, Dbp5p, required for mRNA export out of the nucleus, has recently been shown to be activated by the nuclear pore protein Gle1 and phosphoinositide IP6, suggesting that Dbp5p RNA binding/ATPase activity at

**Keywords:** DEAD box 1, DEAD box protein, gene amplification, MYCN, neuroblastoma, retinoblastoma, RNA helicase

future medicine part of fsg

Figure 1. DEAD box motifs and SPRY domain in DDX1.



DDX1 has the nine conserved motifs found in all DEAD box proteins (Q, I, Ia, Ib, II, III, IV, V and VI), as well as a SPRY domain. The amino acids spanning each conserved motif are indicated, with 740 referring to the total number of amino acids in DDX1. Activities associated with motifs I, II, III and VI are shown in blue. Capital letters represent amino acids that are conserved in the majority (>80%) of DEAD box proteins; small case letters represent amino acids that are less well-conserved (50–79%) [7]. For the Q motif, the asterisk represents 16 amino acids; a = F,W,Y; c = D,E,H,K,R; l = I,L,V; o = S,T [90].

the nuclear pore is necessary for mRNA export [22–24]. Some DEAD box proteins are believed to function as RNPs involved in RNA-protein association and dissociation [25,26]. A recent analysis of p68 function in *Drosophila* has revealed a possible connection between DEAD box proteins, transcript clearance and gene repression [27]. Flies carrying *p68* mutations do not release completed mRNAs from their transcription sites and have problems in shutting off active genes. These authors postulate that p68 may be required to remove transcripts from a gene before the chromatin can be reset to an inactive state.

#### DEAD box proteins & cancer

A number of DEAD box proteins have been implicated in cancer. For example, the *p54* and *DDX10* genes are found at sites of chromosome translocations [28–30] and p54 has been shown to be overexpressed in a number of cancer types [31–33]. As p54 can unwind *c-Myc* RNA *in vitro*, it has been suggested that p54 may contribute to cancer by restructuring mRNAs, thus affecting their translation efficiency. In this regard, it is noteworthy that Myc–Max heterodimers have been implicated in the transcriptional activity of two DEAD box genes: *MrDd* (*DDX18*) and *Drosophila* pitchoune [34,35]. These results suggest a

cancer-related feedback loop between members of the DEAD box protein family and Myc, with Myc activating DEAD box protein transcription and DEAD box proteins promoting Myc production.

Two related DEAD box proteins, p68 and p72 (*DDX17*), can function either as transcriptional coactivators for estrogen receptor- $\alpha$  (*ER* $\alpha$ ) and tumor suppressor p53, or as co-repressors, depending on the promoter context [36–38]. p68 is recruited to the promoter of the *ER* $\alpha$  target gene, *pS2*, in the presence of estrogen and stimulates transcription from p53-responsive promoters, suggesting a direct role in transcriptional regulation [36,37]. Phosphorylation of p68 activates transcription of the cyclin D and *c-Myc* genes resulting in an increase in PDGF-induced cell proliferation [39]. p68 is overexpressed in colorectal cancer and overexpression of this DEAD box protein in normal cells results in their transformation [40,41]. p68 is phosphorylated in cancer cell lines but not in normal cells, suggesting that p68 phosphorylation regulates the activity of genes important for tumor formation [42]. Recently, phosphorylated p68 has been shown to be required for epithelial-mesenchymal transition, a process believed to be critical in enabling epithelial cells to become invasive, by promoting cytoplasmic  $\beta$ -catenin nuclear translocation [43].

DDX3, also known as PL10, An3, CAP-Rf and DBX, has been postulated to play a role in nuclear–cytoplasmic shuttling of RNAs, pre-mRNA splicing, mRNA transport and transcriptional activation. DDX3 upregulates the promoter activity of *CDKN1A* (p21<sup>WAF1/CIP1</sup>) and has an inhibitory effect on cell growth [44]. DDX3 is reduced in hepatoma tumors and is translocated from the nucleus to the cytoplasm in cutaneous squamous cell carcinomas [44]. These data support a role for DDX3 in tumor suppression.

#### DEAD box 1 identification, structure & expression

DEAD box 1 (*DDX1*) was identified by differential screening of a subtracted retinoblastoma cDNA library prepared from two retinoblastoma cell lines, Y79 and RB522A [45]. Subsequent Northern and Southern blot analyses revealed amplified copies of the *DDX1* gene and over-expression of the *DDX1* transcript in a subset of retinoblastoma cell lines with *MYCN* amplification. Like the *MYCN* gene, *DDX1* is located on chromosome 2p24 [45].

In addition to the nine motifs characteristic of DEAD box proteins, DDX1 has a SPRY domain of around 130 amino acids. Although the function of SPRY domains remains enigmatic, they are believed to play a role in either protein–protein or protein–RNA interactions (Figure 1) [46–49]. SPRY domains have been identified in more than 70 proteins encoded by the human genome, including heterogeneous nuclear ribonucleoprotein (hnRNP) U and RanBPM. In hnRNP U, the region encoding the SPRY domain mediates binding of TFIIH to the RNA polymerase II holoenzyme [50]. RanBPM binds to the neurotrophin receptor TrkA through its SPRY domain [51].

Sequence comparison analysis reveals little about the function of DDX1 as the predicted amino acid sequence of DDX1 is approximately 30% identical (over the core 350 amino acid region containing the nine conserved motifs) to other DEAD box proteins, regardless of species. The evolutionary relationship of DDX1 to other members of the human DEAD box protein family is illustrated in Figure 2. While DDX1 is not closely related to any of the other human DEAD box proteins, its closest relatives appear to be DDX2 (eIF-4A), DDX6 (p54), DDX19, DDX20, DDX25, DDX39 and DDX48.

DDX1 is expressed in all tissues and cell lines tested to date, with the highest levels found in proliferating cells, cancer cells and cells of neuroectodermal origin [45,52]. *In silico* analysis of DDX1 tissue distribution reveals the highest levels of *DDX1* RNA in adult eye and brain compared with other adult tissues (Figure 3). With the exception of retinoblastoma and nonglioma brain tumors, which have significantly higher numbers of *DDX1*-expressed sequence tags in tumor compared with normal tissue, *DDX1* RNA levels appear similar in normal and cancer cells. DDX1 orthologues are found in rodents (*Mus musculus*, *Rattus norvegicus*), chicken (*Gallus gallus*), zebrafish (*Danio rerio*), fruit fly (*Drosophila melanogaster*), and nematode (*Caenorhabditis elegans*; the putative Y55F3BR.1 protein) (Table 1).

#### Coamplification of *DDX1* & *MYCN*

The *DDX1* gene is coamplified with the *MYCN* gene in four childhood tumors: retinoblastoma (of 30 retinoblastoma cell lines tested, four were *MYCN*- and *DDX1*-amplified; none of the lines with normal *MYCN* copy numbers were amplified for *DDX1*) [45, Our Unpublished Data], neuroblastoma (1/2 to 2/3 of *MYCN*-amplified cell lines and tumors) [53–56], alveolar rhabdomyosarcoma (6/6 *MYCN*-amplified tumors) [57] and medulloblastoma (1/1 *MYCN*-amplified tumor) [58]. There is a strong correlation between *DDX1* gene copy number, *DDX1* mRNA levels and DDX1 protein levels in *DDX1*-amplified retinoblastoma and neuroblastoma tumor cell lines and tissues [56,59,60].


The *MYCN* amplification unit usually ranges from 300,000 to more than 1 million base pairs. A core amplification domain of approximately 130 kb was identified by analyzing the commonly amplified DNA regions in

**Table 1. Comparison of the predicted amino acid sequences of DDX1 proteins from different species.**

Species	Identity (%)*
<i>Homo sapiens</i>	100
<i>Rattus norvegicus</i>	97.7
<i>Mus musculus</i>	97.5
<i>Gallus gallus</i>	93.2
<i>Danio rerio</i>	84.1
<i>Drosophila melanogaster</i>	58.7
<i>Caenorhabditis elegans</i>	46.5

\*Percent identity is shown relative to human *DDX1*. The *Danio rerio* (zebrafish) sequence was compiled from CAH68924 and CAI20707.

**Figure 2. Evolutionary relationship of human *DDX1* with other human DEAD box proteins.**



Amino acid sequences of 35 human DEAD box proteins were obtained from the NCBI website [101]. Alternative names are shown after the official DDX designation with the roles of the better characterized DEAD box proteins indicated in parentheses. The bootstrap neighbour-joining tree was constructed with CLUSTALX [91]. Positions with gaps were excluded for the analysis. The bootstrap values (based on number/1000 replicate trials) are indicated on each node.

33 *MYCN*-amplified neuroblastoma tumors. The core domain amplified in 32 out of 33 tumors consists of the *MYCN* gene, 5 kb of DNA telomeric to *MYCN* and 125 kb of centromeric DNA [61]. *DDX1* is located outside

the core amplification domain, approximately 310 kb telomeric of *MYCN*. As DNA mutations and rearrangements are common in amplified DNA regions, it is generally believed that only those amplified genes that provide a

growth advantage to a cell or tumor will be overexpressed. *DDX1* overexpression in *DDX1*-amplified cells suggests that elevated levels of this protein play an important role in either the development or maintenance of retinoblastoma and neuroblastoma tumors.


A number of genes other than *DDX1* have been reported to be amplified with *MYCN* in neuroblastoma. These include *NAG* (neuroblastoma-amplified gene), DNA repair protein *NSE1*, *LPIN1* (lipin 1), *SMC6* (structural maintenance of chromosome 6) and *SDC1* (syndecan 1). Of the *MYCN*-coamplified genes, *DDX1* is most consistently amplified and overexpressed in neuroblastoma tumors, followed by *NAG*, which is 380 kb telomeric to *MYCN* (Figure 4) [60,62].

There is evidence that the *DDX1* protein itself may be tumorigenic. Transfection of NIH3T3 cells with a *DDX1* expression vector results in the formation of colonies that demonstrate many hallmarks of cell transformation, including increased growth rates, increased anchorage independence and the ability to form tumors in nude mice [63].

### Prognostic significance of *DDX1* amplification


Retinoblastoma is a relatively rare tumor of the eye with a worldwide incidence of approximately 1 in 20,000 live births. An estimated 40% of retinoblastomas are a direct consequence of germline mutations in the *RBI* gene on chromosome 13q14, with tumors arising when the remaining normal copy of the *RBI* gene is inactivated. Children with the heritable form of retinoblastoma have multiple tumor foci distributed in one eye (unilateral) or both eyes (bilateral). Nonhereditary retinoblastoma is unilateral and unifocal since the likelihood of randomly inactivating both copies of the *RBI* gene in more than one target cell in the same individual is exceedingly small. Based on age at diagnosis of bilateral versus unilateral retinoblastoma, Knudson estimated that only two mutations are required for retinoblastoma onset [64]. These data have led to the hypothesis that complete inactivation of the *RBI* gene is sufficient for the development of retinoblastoma. However, in addition to the loss of *RBI* gene function, retinoblastoma tumors harbor a number of common cytogenetic

**Figure 3. *DDX1*-expressed sequence tags in cDNA libraries generated from human normal and cancerous tissues.**



Expressed sequence tag (EST) counts for each tissue, standardized as number of transcripts per million (TPM), were obtained from UniGene [102]. The number of *DDX1* ESTs per total number of ESTs analyzed for each tissue is as follows: normal eye tissue (171/199770), retinoblastoma (158/46540), normal brain (396/940132), nonglioma brain tumor (294/131694), glioma brain tumor (9/107372), normal adrenal gland (6/33090), adrenal tumor (4/12709), normal liver (30/206292), liver tumor (13/96035), normal ovary (13/101514), ovarian tumor (13/76350), normal skin (41/197072), skin tumor (25/124904), normal muscle (6/107044), soft tissue/muscle tissue tumor (10/125489), normal bone (12/71669), bone tumor (15/99678), normal kidney (35/211066), kidney tumor (16/69067), normal mammary gland (22/152723), breast cancer (18/93685), normal prostate (12/191102), prostate tumor (6/111058), normal pancreas (11/214133), pancreatic tumor (5/104993), normal uterus (36/233118) and uterine tumor (13/90467).

**Figure 4. Map of *MYCN* and neighboring genes on chromosome 2p24.**



abnormalities, including the acquisition of genetic material at chromosome 6p (usually in the form of an isochromosome 6p) and chromosome 1q [65], suggesting that additional events may be necessary for retinoblastoma tumor formation. In support of this idea, retinomas, benign retinal tumors, are often found in retinoblastoma patients [66], suggesting that initiating events may not be sufficient for malignant cell transformation. Preliminary analysis indicates that these lesions have mutations in both copies of the *RBI* gene [67].

*MYCN* amplification has been reported in approximately 5–15% of retinoblastomas [68], with *MYCN*-amplified tumors exhibiting increased levels of *MYCN* RNA and protein [69]. Although the *MYCN* amplicon is not as well characterized in retinoblastoma as it is in neuroblastoma, it is noteworthy that *DDX1* is coamplified with *MYCN* in all four *MYCN*-amplified retinoblastoma cell lines identified to date. As the cure rate for retinoblastoma is generally very high, with enucleation being the most common

treatment, it may be difficult to address the clinical significance of *MYCN* or *MYCN/DDX1* amplification in retinoblastoma.

*MYCN* amplification is observed in approximately 25% of neuroblastoma tumors and is strongly associated with a poor prognosis. The 6-year survival probability for all patients with neuroblastoma is approximately 60%, compared to less than 30% for neuroblastoma patients with *MYCN* amplification. The fact that some patients with *MYCN* amplification are long-term survivors suggests that factors other than *MYCN* determine patient outcome. Two early reports that included relatively small numbers of *MYCN*-amplified neuroblastoma tumors (13 cases in the first study, 38 cases in the second study) showed a trend towards a worse clinical prognosis in *MYCN/DDX1*-amplified tumors in comparison with *MYCN*-amplified tumors [54,70]. However, more recent studies including larger cohorts suggest a better prognosis if *DDX1* is coamplified with *MYCN*. For example, analysis of 98 *MYCN*-amplified primary neuroblastomas revealed a better clinical outcome when *DDX1* was coamplified with *MYCN* ( $p = 0.027$ ) [56]. There was no correlation with outcome for the other *MYCN*-coamplified genes tested, such as *NAG*, *NSE1*, *LPIN1*, *EST-AA581763*, *SMC6* and *SDC1*. Importantly, Weber *et al.* noted that 35% of patients with *DDX1/MYCN* coamplification diagnosed before 1996 (with a minimum follow-up time of 6 years) were long-term survivors in contrast with patients without *DDX1* amplification, all of whom died within 28 months of initial diagnosis ( $p = 0.01$ ) [56]. Although these data were contested by a second group who found no adverse or beneficial prognostic value associated with *DDX1* amplification [71], the difference in results between the two groups could be accounted for by the lower survival probability of the patient cohort in the De Preter *et al.* study (10–15%) compared with the Weber *et al.* study (20–25%). In yet another report, 113 primary neuroblastoma tumors were examined for *MYCN*, *DDX1* and *NAG* amplification and expression. Patients aged 18 months or older were found to have a significantly better outcome if *DDX1*, but not *NAG*, was coamplified with *MYCN* [60]. These data have led to the hypothesis that overexpression of *DDX1* may make the tumor more susceptible to therapy. Further insight into the role of *DDX1* amplification and overexpression in clinical prognosis will require analysis of additional cohorts of uniformly treated patients.


### Subcellular localization of DDX1

DDX1 is primarily located in the nucleus of non-*DDX1*-amplified cells (Figure 5) [59]. However, in *DDX1*-amplified cells, DDX1 is abundant in both the nucleus and cytoplasm, with a staining intensity in the nucleus similar to that of nonamplified cells (Figure 5). The fact that nuclear DDX1 does not appreciably increase in *DDX1*-amplified cells suggests that DDX1 levels in the nucleus may be regulated. DDX1 has a punctate pattern in the nucleus and is generally excluded from the nucleoli. In most normal and cancer cells, DDX1 can also be found in dense foci of approximately 0.5  $\mu\text{m}$  (usually 2–3 per cell), known as DDX1 nuclear bodies [72,73].

Different types of nuclear bodies, including cleavage bodies, Cajal bodies and gems, have been identified in the nucleus. Cleavage bodies, Cajal

bodies and gems all contain proteins associated with RNA metabolism and have been proposed to serve as storage or assembly sites for factors involved in RNA synthesis, splicing, processing and degradation. Protein markers specific for each nuclear body (cleavage stimulation factor [CstF]-64 for cleavage bodies, p80 coilin or the splicing-associated factor Sm for Cajal bodies and SMN for gems) have been used to examine the spatial relationship of DDX1 and other nuclear bodies as a function of the cell cycle. DDX1 nuclear bodies were found to colocalize with cleavage bodies and to reside adjacent to Cajal bodies and gems during the S phase of the cell cycle [73]. Fluorescence resonance energy transfer and co-immunoprecipitation indicate that DDX1 is not only in close proximity to CstF-64 but also exists in a complex with this protein [72].

**Figure 5. Distribution of DDX1 protein in KAN and LA-N-1 neuroblastoma cell lines.**



CstF is a heterotrimeric complex (CstF-64, CstF-77 and CstF-50) involved in the 3' end processing of pre-mRNAs. The cleavage and polyadenylation steps associated with 3' end processing require the AAUAAA hexanucleotide, which is located 10–30 bases upstream of the cleavage site, and a GU- or U-rich element located 20–40 bases downstream of the cleavage site. The AAUAAA sequence is bound by the cleavage and polyadenylation specificity factor complex, whereas the GU element is bound by the CstF complex, with CstF-64 shown to bind directly to the RNA [74]. In support of a role for DDX1 in 3' end processing, Sunden *et al.* [75] demonstrated an interaction between DDX1 and CstF-77 using the yeast-two-hybrid system. DDX1 also binds hnRNP K, a multifunctional protein associated with the regulation of transcription, mRNA export, splicing and translation initiation, as well as to poly(A) *in vitro* [76]. The association of DDX1 with CstF-64, CstF-77 and hnRNP K links DDX1 to RNA processing and/or events associated with RNA processing, such as translation initiation and nuclear export.

#### DDX1 & RNA transport/translation

Kanai *et al.* identified 42 proteins in RNA-transporting granules of neurons that were isolated as binding partners of kinesin KIF5, including DDX1, DDX3 and elongation factor-1  $\alpha$  (eEF1A) [77]. Through coimmunoprecipitation experiments, DDX1 was found in the same complex as eEF1A, a protein involved in translation. These authors postulate that DEAD box proteins located in RNA-transporting granules may play a role in translation initiation similar to that of eIF4A. As an alternative, they propose that DDX1 could play a role in RNA transport, perhaps through interaction with kinesin along microtubules.

DDX1 has been shown to associate with proteins found in pseudopodial protrusions, along with DDX3 and DDX13, and proteins involved in cell signaling such as RACK1, IQGAP1, RhoGD1 and ROCK. The discovery of DEAD box proteins in these structures has led to the hypothesis that pseudopodial proteins may be involved in the recruitment of RNAs for local translation [78]. DDX1 also associates with 14–3–3 proteins [79,80]. 14–3–3 proteins have been implicated in the regulation of a wide range of cellular processes, including cellular trafficking, transcription, RNA processing, protein synthesis and cell cycle.

#### DDX1 & viral infection

DDX1 plays an important role in the function of Rev, an early gene product expressed during the HIV-1 replication cycle [81]. All HIV-1 proteins are made from a single transcript in its spliced and unspliced forms. Rev binds to the Rev-responsive element, a structured RNA sequence present in the viral transcripts. Rev, with CRM1 as a cofactor, allows nuclear export of transcripts containing introns. DDX1, as well as DDX3, has been shown to interact with Rev and to play critical roles in the export of incompletely spliced HIV-1 RNAs [81,82]. As these results suggest that DDX1 may facilitate HIV-1 replication, this has led to speculation that DEAD box proteins could be used in novel anti-HIV-1 strategies and therapeutics. In agreement with this, endogenous DDX1 alters the distribution of Rev protein in astrocytes, resulting in an unfavorable microenvironment for Rev function [83].

DDX1 enhances production of the JC virus, a human polyomavirus, by transactivating the JC virus promoter when overexpressed in HEK293 cells [84]. DDX1 has also been shown to bind to the 3'(+)-untranslated region (UTR) and reverse complementarity 5'(-) UTR of HCV [85]. As the 3' UTR is believed to play a role in the initiation and regulation of viral RNA replication and protein translation, binding of DDX1 to this region may be important for viral replication.

#### Conclusion

Retinoblastoma appears to be a genetically simple and well-characterized tumor, with inactivation of both copies of the *RBI* gene apparently sufficient to at least initiate tumor formation. Yet, a number of recurrent chromosome abnormalities, including *MYCN* and *DDX1* amplification, and the presence of *RBI*<sup>-/-</sup> benign retinomas in retinoblastoma patients, suggest that additional events may be required to produce the highly malignant phenotype characteristic of these tumors. Furthermore, in spite of extensive mutational analysis, *RBI* mutations in the blood and tumor tissue of patients with retinoblastoma are not always found [86], leaving the door open to the possibility that not all retinoblastomas are initiated as a consequence of loss of *RBI* function.

Although neuroblastoma is not, in genetic terms, as well characterized as retinoblastoma, a number of chromosome abnormalities have been associated with neuroblastoma, including deletions of the short arm of chromosome 1

(25–35% of tumors) and loss of 11q (35–45% of primary tumors) [87]. *MYCN* amplification/overexpression (~25% of primary tumors) is most consistently associated with a poor clinical outcome in neuroblastoma. The effectors of *MYCN* underlying the aggressive nature of *MYCN*-amplified neuroblastomas have not been conclusively identified. The coamplification of *DDX1* commonly observed in *MYCN*-amplified neuroblastoma suggests a possible role for *DDX1* in these tumors.

Based on the proposed roles for DEAD box proteins, overexpression of *DDX1* in retinoblastoma, neuroblastoma and other tumor cells could have profound effects on transcript levels, RNA transport and protein production. *DDX1* has been shown to associate with factors involved in the processing of pre-mRNAs (CstF-64, CstF-77 and 14–3-3), RNA transport and transcription (hnRNP K, Rev and 14–3-3) and translation (eEF1A). As these processes are inter-related, and *DDX1* is found in both the cytoplasm and nucleus, we propose that *DDX1* may be linked to mRNAs from the time that they are transcribed in the nucleus to the time they are translated in the cytoplasm. Since *DDX1* is specifically enriched in the cytoplasm of *DDX1*-amplified cells, we further propose that the end result of *DDX1* overexpression may be spatial and/or quantitative abnormalities in protein distribution and/or production.

Insight into the function of *DDX1* in normal and cancer cells will require a better understanding of the natural *DDX1* substrates. Substrates synthesized *in vitro* typically used in RNA helicase/unwinding assays consist of 10–14 bp of dsRNA flanked by relatively long ssRNA ends. Chen *et al.* found that immunoprecipitated *DDX1*, but not recombinant *DDX1*, was able to unwind an RNA substrate containing 10 bp, but not 14 bp, of dsRNA, leading to the suggestion that cofactors are required for RNA helicase activity [76]. However, until we identify the endogenous substrates of *DDX1* and the proteins with which *DDX1* interacts, only limited information can be derived from these experiments. *DDX1*–RNA and *DDX1*–protein coimmunoprecipitation experiments may shed light on the types of molecules that are preferentially bound by *DDX1*. Alternatively, a genomic or proteomic approach revealing which transcripts or proteins are altered as a consequence of *DDX1* overexpression may provide information on the types of molecules targeted by *DDX1*.

*DDX1* amplification is consistently accompanied by a significant increase in *DDX1* RNA and protein, suggesting that increased *DDX1* expression in *MYCN*-amplified tumors may provide either a growth or survival advantage. In this regard, it is interesting that other DEAD box proteins (p54, p68, MrDr and pitchoune) have been associated with Myc [32,34,35,39]. An intriguing possibility is that cross-talk occurs between *DDX1* and *MYCN*. Thus, elevated levels of *DDX1* may enhance, balance or even counteract the oncogenic properties of *MYCN*.

In spite of extensive research, DEAD box proteins remain enigmatic molecules. Some of these proteins may be critically involved in a range of fundamental RNA metabolic processes, making it difficult to pinpoint their exact roles in the cell. Others may play specialized roles when associated with their natural substrates and cofactors, conditions that have yet to be reproduced in the laboratory. Future insight into the role of *DDX1* in normal and cancer cells will come from the identification of its natural substrates and the cofactors with which it interacts.

#### Future perspective

Endogenous substrates of *DDX1*, as well as *DDX1* interactors and cofactors, need to be identified if significant progress is to be made in understanding the biological consequence of *DDX1* overexpression in tumors. Identification of the molecules that *DDX1* interacts with will provide a more relevant context for examining its biochemical properties and biological role in the cell.

With the exception of one report indicating that *DDX1* overexpression results in transformation of NIH3T3 cells, the consequences of experimentally manipulating *DDX1* levels have not been addressed in higher eukaryotes. In *Drosophila*, *DDX1* mutations are associated with an embryonic recessive lethal phenotype [103]. We are currently attempting to generate *DDX1*<sup>-/-</sup> mice to address the role of *DDX1* during development. Our attempts to overexpress *DDX1* in transgenic mice have been unsuccessful even though the *DDX1* gene was inserted in the genome in multiple copies, suggesting that levels of *DDX1* may be regulated in nontumorigenic cells. Models need to be developed that allow manipulation of intracellular levels of *DDX1* in both normal and tumor cells if we are to make progress in understanding its function.

Finally, *MYCN*-amplified and *MYCN/DDX1*-amplified neuroblastoma tumors provide a natural model system to investigate the consequence

of *DDX1* overexpression on tumor growth properties. Analysis of sufficient numbers of *DDX1/MYCN*-amplified versus *MYCN*-amplified neuroblastoma patients should resolve the issue of whether or not *DDX1* amplification affects patient prognosis. Should *DDX1* amplification and overexpression turn out to be associated with a worse prognosis, there may be ways of targeting *DDX1*-overexpressing tumor cells as part of the therapeutic regimen. For example, a small molecule inhibitor of translation initiation, pateamine, has recently been shown to function through uncontrolled stimulation of eIF4A-associated activities [88]. Furthermore, the tumor suppressor *Pdc4* can bind eIF4A, thus inhibiting its RNA helicase activity and cap-dependent translation of proteins [89]. Identification of molecules and proteins that interact with *DDX1* may provide reagents that can be used to inhibit

or limit its activity in tumor cells. On the other hand, should *DDX1* amplification and overexpression provide a clinical advantage to patients with neuroblastoma, this may lead to a more individualized approach to the treatment of *MYCN*-amplified versus *MYCN/DDX1*-amplified neuroblastoma tumors.

#### Financial & competing interests disclosure

*The authors work is supported by the National Cancer Institute of Canada with funds from the Canadian Cancer Society and by a Research Initiative Program grant from the Alberta Cancer Board. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.*

*No writing assistance was utilized in the production of this manuscript.*

#### Executive summary

- DEAD box proteins are ubiquitously expressed proteins implicated in all aspects of RNA metabolism.
- *DDX1* is expressed in every cell type tested to date and enriched in cells of neuroectodermal origin.
- *DDX1* is amplified with *MYCN* and overexpressed in a subset of retinoblastoma and neuroblastoma tumors.
- The clinical significance of *DDX1* amplification in *MYCN*-amplified neuroblastoma remains controversial, although recent studies suggest improved survival when *DDX1* is coamplified with *MYCN*.
- *DDX1* is expressed in both the cytoplasm and nucleus. In the nucleus, *DDX1* has a punctate distribution pattern and is also found in nuclear bodies.
- During the S phase of the cell cycle, *DDX1* nuclear bodies colocalize with cleavage bodies, with *DDX1* bodies and cleavage bodies residing adjacent to Cajal bodies and gems.
- Cleavage stimulation factor-64 and -77, heterogeneous nuclear ribonucleoprotein K and elongation factor-1 alpha have been shown to exist in the same complex as *DDX1*, suggesting roles in processing 3' ends of pre-mRNAs, as well as in RNA transport and transcription.
- *DDX1* is found in RNA-transporting granules of neurons.
- We propose that *DDX1* is a multifunctional RNA transport protein involved in facilitating the processing and translation of transcripts.

#### Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Linder P: Dead-box proteins: a family affair—active and passive players in RNP-remodeling. *Nucleic Acids Res.* 34(15), 4168–4180 (2006).
2. Cordin O, Tanner NK, Doere M, Linder P, Banroques J: The newly discovered Q motif of DEAD-box RNA helicases regulates RNA-binding and helicase activity. *EMBO J.* 23(13), 2478–2487 (2004).
3. Rocak S, Linder P: DEAD-box proteins: the driving forces behind RNA metabolism. *Nat. Rev. Mol. Cell. Biol.* 5(3), 232–241 (2004).
4. Rocak S, Emery B, Tanner NK, Linder P: Characterization of the ATPase and unwinding activities of the yeast DEAD-box protein Has1p and the analysis of the roles of the conserved motifs. *Nucleic Acids Res.* 33(3), 999–1009 (2005).
5. Abdelhaleem M, Maltais L, Wain H: The human *DDX* and *DHX* gene families of putative RNA helicases. *Genomics* 81(6), 618–622 (2003).
6. Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM: Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. *Nucleic Acids Res.* 17(12), 4713–4730 (1989).
7. Tanner NK, Linder P: DExD/H box RNA helicases: from generic motors to specific dissociation functions. *Mol. Cell* 8(2), 251–262 (2001).
8. Jankowsky E, Gross CH, Shuman S, Pyle AM: The DExH protein NPH-II is a processive and

- directional motor for unwinding RNA. *Nature* 403(6768), 447–451 (2000).
9. Pause A, Sonenberg N: Mutational analysis of a DEAD box RNA helicase: the mammalian translation initiation factor eIF-4A. *EMBO J.* 11(7), 2643–2654 (1992).
  10. Rogers GW Jr, Komar AA, Merrick WC: eIF4A: the godfather of the DEAD box helicases. *Prog. Nucleic Acid Res. Mol. Biol.* 72, 307–331 (2002).
  11. Oberer M, Marintchev A, Wagner G: Structural basis for the enhancement of eIF4A helicase activity by eIF4G. *Genes Dev.* 19(18), 2212–2223 (2005).
  12. Rogers GW Jr, Richter NJ, Lima WF, Merrick WC: Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. *J. Biol. Chem.* 276(33), 30914–30922 (2001).
  13. Rozen F, Ederly I, Meerovitch K *et al.*: Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4E. *Mol. Cell Biol.* 10(3), 1134–1144 (1990).
  14. Svitkin YV, Pause A, Haghghat A *et al.*: The requirement for eukaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. *RNA* 7(3), 382–394 (2001).
  15. Tseng SS, Weaver PL, Liu Y *et al.*: Dbp5p, a cytosolic RNA helicase, is required for poly(A)+ RNA export. *EMBO J.* 17(9), 2651–2662 (1998).
  16. Hirling H, Scheffner M, Restle T, Stahl H: RNA helicase activity associated with the human p68 protein. *Nature* 339(6225), 562–564 (1989).
  17. Iggo RD, Lane DP: Nuclear protein p68 is an RNA-dependent ATPase. *EMBO J.* 8(6), 1827–1831 (1989).
  18. Gururajan R, Mathews L, Longo FJ, Weeks DL: *An3* mRNA encodes an RNA helicase that colocalizes with nucleoli in Xenopus oocytes in a stage-specific manner. *Proc. Natl Acad. Sci. USA* 91(6), 2056–2060 (1994).
  19. Liang L, Diehl-Jones W, Lasko P: Localization of vasa protein to the *Drosophila* pole plasm is independent of its RNA-binding and helicase activities. *Development* 120(5), 1201–1211 (1994).
  20. Ladomery M, Wade E, Sommerville J: Xp54, the Xenopus homologue of human RNA helicase p54, is an integral component of stored mRNP particles in oocytes. *Nucleic Acids Res.* 25(5), 965–973 (1997).
  21. Lorsch JR: RNA chaperones exist and DEAD box proteins get a life. *Cell* 109(7), 797–800 (2002).
  22. Weirich CS, Erzberger JB, Flick JS *et al.*: Activation of the DExD/H-box protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator InsP6 is required for mRNA export. *Nat. Cell Biol.* 8(7), 668–676 (2006).
  23. Alcazar-Roman AR, Tran EJ, Guo S, Wente SR: Inositol hexakisphosphate and Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export. *Nat. Cell Biol.* 8(7), 711–716 (2006).
  24. Cole CN, Scarcelli JJ: Transport of messenger RNA from the nucleus to the cytoplasm. *Curr. Opin. Cell Biol.* 18(3), 299–306 (2006).
  25. Schwer B: A new twist on RNA helicases: DExH/D box proteins as RNPsases. *Nat. Struct. Biol.* 8(2), 113–116 (2001).
  26. Fairman ME, Maroney PA, Wang W *et al.*: Protein displacement by DExH/D 'RNA helicases' without duplex unwinding. *Science* 304(5671), 730–734 (2004).
  27. Buszczak M, Spradling AC: The *Drosophila* P68 RNA helicase regulates transcriptional deactivation by promoting RNA release from chromatin. *Genes Dev.* 20(8), 977–989 (2006).
  28. Akao Y, Seto M, Yamamoto K *et al.*: The *RCK* gene associated with t(11;14) translocation is distinct from the *MLL/ALL-1* gene with t(4;11) and t(11;19) translocations. *Cancer Res.* 52(21), 6083–6087 (1992).
  29. Lu D, Yunis JJ: Cloning, expression and localization of an RNA helicase gene from a human lymphoid cell line with chromosomal breakpoint 11q23.3. *Nucleic Acids Res.* 20(8), 1967–1972 (1992).
  30. Arai Y, Hosoda F, Kobayashi H *et al.*: The inv(11)(p15q22) chromosome translocation of *de novo* and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, *NUP98*, with the putative RNA helicase gene, *DDX10*. *Blood* 89(11), 3936–3944 (1997).
  31. Miyaji K, Nakagawa Y, Matsumoto K *et al.*: Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis. *J. Viral Hepat.* 10(4), 241–248 (2003).
  32. Akao Y, Yoshida H, Matsumoto K *et al.*: A tumour-associated DEAD-box protein, rck/p54 exhibits RNA unwinding activity toward c-myc RNAs *in vitro*. *Genes Cells* 8(8), 671–676 (2003).
  33. Matsui T, Hogetsu K, Akao Y *et al.*: Crystallization and x-ray analysis of the N-terminal core domain of a tumour-associated human DEAD-box RNA helicase, rck/p54. *Acta Crystallogr. D. Biol. Crystallogr.* 60(Pt 1), 156–159 (2004).
  34. Grandori C, Mac J, Siebelt F, Ayer DE, Eisenman RN: Myc–Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites *in vivo*. *EMBO J.* 15(16), 4344–4357 (1996).
  35. Zaffran S, Chartier A, Gallant P *et al.*: A *Drosophila* RNA helicase gene, pitchoune, is required for cell growth and proliferation and is a potential target of d-Myc. *Development* 125(18), 3571–3584 (1998).
  36. Metivier R, Penot G, Hubner MR *et al.*: Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* 115(6), 751–763 (2003).
  37. Bates GJ, Nicol SM, Wilson BJ *et al.*: The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. *EMBO J.* 24(3), 543–553 (2005).
  38. Wilson BJ, Bates GJ, Nicol SM *et al.*: The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. *BMC Mol. Biol.* 5, 11 (2004).
  39. Yang L, Lin C, Zhao S, Wang H, Liu ZR: Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. *J. Biol. Chem.* 282(23), 16811–16819 (2007).
  40. Causevic M, Hislop RG, Kernohan NM *et al.*: Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. *Oncogene* 20(53), 7734–7743 (2001).
  41. Wei Y, Hu MH: The study of P68 RNA helicase on cell transformation. *Yi Chuan Xue Bao* 28(11), 991–996 (2001).
  42. Yang L, Lin C, Liu ZR: Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. *Mol. Cancer Res.* 3(6), 355–363 (2005).
  43. Yang L, Lin C, Liu ZR: P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. *Cell* 127(1), 139–155 (2006).
  44. Chao CH, Chen CM, Cheng PL *et al.*: DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the *p21waf1/cip1* promoter, is a candidate tumor suppressor. *Cancer Res.* 66(13), 6579–6588 (2006).

45. Godbout R, Squire J: Amplification of a DEAD box protein gene in retinoblastoma cell lines. *Proc. Natl Acad. Sci. USA* 90(16), 7578–7582 (1993).
- **Discovery that a novel DEAD box protein gene (*DDX1*) is coamplified with *MYCN* and overexpressed in a subset of retinoblastoma tumors**
46. Godbout R, Hale M, Bisgrove D: A human DEAD box protein with partial homology to heterogeneous nuclear ribonucleoprotein U. *Gene* 138(1–2), 243–245 (1994).
47. Hilton DJ, Richardson RT, Alexander WS *et al.*: Twenty proteins containing a C-terminal SOCS box form five structural classes. *Proc. Natl Acad. Sci. USA* 95(1), 114–119 (1998).
48. Ponting C, Schultz J, Bork P: SPRY domains in ryanodine receptors (Ca<sup>2+</sup>-release channels). *Trends Biochem. Sci.* 22(6), 193–194 (1997).
49. Rhodes DA, de Bono B, Trowsdale J: Relationship between SPRY and B30.2 protein domains. Evolution of a component of immune defence? *Immunology* 116(4), 411–417 (2005).
50. Kim MK, Nikodem VM: hnRNP U inhibits carboxy-terminal domain phosphorylation by TFIIF and represses RNA polymerase II elongation. *Mol. Cell. Biol.* 19(10), 6833–6844 (1999).
51. Yuan Y, Fu C, Chen H *et al.*: The Ran binding protein RanBPM interacts with TrkA receptor. *Neurosci. Lett.* 407(1), 26–31 (2006).
52. Godbout R, Packer M, Katyal S, Bleoo S: Cloning and expression analysis of the chicken DEAD box gene *DDX1*. *Biochim Biophys. Acta* 1574(1), 63–71 (2002).
53. Manohar CF, Salwen HR, Brodeur GM, Cohn SL: Co-amplification and concomitant high levels of expression of a DEAD box gene with *MYCN* in human neuroblastoma. *Genes Chromosomes Cancer* 14(3), 196–203 (1995).
- **One of three first reports indicating that *DDX1* is coamplified with *MYCN* in neuroblastoma.**
54. Squire JA, Thorner PS, Weitzman S *et al.*: Co-amplification of *MYCN* and a DEAD box gene (*DDX1*) in primary neuroblastoma. *Oncogene* 10(7), 1417–1422 (1995).
- **One of three first reports indicating that *DDX1* is coamplified with *MYCN* in neuroblastoma.**
55. George RE, Kenyon RM, McGuckin AG *et al.*: Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and DEAD box gene, *DDX1*, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. *Oncogene* 12(7), 1583–1587 (1996).
- **One of three first reports indicating that *DDX1* is coamplified with *MYCN* in neuroblastoma.**
56. Weber A, Imisch P, Bergmann E, Christiansen H: Coamplification of *DDX1* correlates with an improved survival probability in children with *MYCN*-amplified human neuroblastoma. *J. Clin. Oncol.* 22(13), 2681–2690 (2004).
- **Coamplification of *DDX1* with *MYCN* in neuroblastoma is associated with a better prognosis.**
57. Pandita A, Zielenska M, Thorner P *et al.*: Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. *Neoplasia* 1(3), 262–275 (1999).
58. Lo KC, Rossi MR, Burkhardt T, Pomeroy SL, Cowell JK: Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. *Genes Chromosomes Cancer* 46(1), 53–66 (2007).
59. Godbout R, Packer M, Bie W: Overexpression of a DEAD box protein (*DDX1*) in neuroblastoma and retinoblastoma cell lines. *J. Biol. Chem.* 273(33), 21161–21168 (1998).
60. Kaneko S, Ohira M, Nakamura Y *et al.*: Relationship of *DDX1* and *NAG* gene amplification/overexpression to the prognosis of patients with *MYCN*-amplified neuroblastoma. *J. Cancer Res. Clin. Oncol.* 133(3), 185–192 (2007).
61. Reiter JL, Brodeur GM: High-resolution mapping of a 130-kb core region of the *MYCN* amplicon in neuroblastomas. *Genomics* 32(1), 97–103 (1996).
62. Weber A, Starke S, Bergmann E, Christiansen H: The coamplification pattern of the *MYCN* amplicon is an invariable attribute of most *MYCN*-amplified human neuroblastomas. *Clin. Cancer Res.* 12(24), 7316–7321 (2006).
63. Scott D, Elsdon J, Pearson A, Lunec J: Genes co-amplified with *MYCN* in neuroblastoma: silent passengers or co-determinants of phenotype? *Cancer Lett.* 197(1–2), 81–86 (2003).
64. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. *Proc. Natl Acad. Sci. USA* 68(4), 820–823 (1971).
65. Corson TW, Gallie BL: One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. *Genes Chromosomes Cancer* 46(7), 617–634 (2007).
66. Balmer A, Munier F, Gailloud C: Retinoma and phtisis bulbi: benign expression of retinoblastoma. *Klin Monatsbl Augenheilkd* 200(5), 436–439 (1992).
67. Dimaras H, Halliday W, Khetan V, Prigoda N, Orlic M, Gallie B: Molecular progression from retinoma to retinoblastoma. Presented at: *11th International Congress of Human Genetics*. Brisbane, Australia, 6–10 August, 2006.
68. Bowles E, Corson TW, Bayani J *et al.*: Profiling genomic copy number changes in retinoblastoma beyond loss of *RBI*. *Genes Chromosomes Cancer* 46(2), 118–129 (2007).
69. Squire J, Goddard AD, Canton M *et al.*: Tumour induction by the retinoblastoma mutation is independent of N-myc expression. *Nature* 322(6079), 555–557 (1986).
70. George RE, Kenyon R, McGuckin AG *et al.*: Analysis of candidate gene co-amplification with *MYCN* in neuroblastoma. *Eur. J. Cancer* 33(12), 2037–2042 (1997).
71. De Preter K, Speleman F, Combaret V *et al.*: No evidence for correlation of *DDX1* gene amplification with improved survival probability in patients with *MYCN*-amplified neuroblastomas. *J. Clin. Oncol.* 23(13), 3167–3168 (2005).
72. Bleoo S, Sun X, Hendzel MJ *et al.*: Association of human DEAD box protein *DDX1* with a cleavage stimulation factor involved in 3'-end processing of pre-mRNA. *Mol. Biol. Cell* 12(10), 3046–3059 (2001).
- ***DDX1* is associated with cleavage bodies and cleavage factor CstF-64.**
73. Li L, Roy K, Katyal S *et al.*: Dynamic nature of cleavage bodies and their spatial relationship to *DDX1* bodies, Cajal bodies, and gems. *Mol. Biol. Cell* 17(3), 1126–1140 (2006).
74. Takagaki Y, Manley JL: RNA recognition by the human polyadenylation factor CstF. *Mol. Cell. Biol.* 17(7), 3907–3914 (1997).
75. Sunden Y, Semba S, Suzuki T *et al.*: Identification of *DDX1* as a JC virus transcriptional control region-binding protein. *Microbiol. Immunol.* 51(3), 327–337 (2007).
76. Chen HC, Lin WC, Tsay YG, Lee SC, Chang CJ: An RNA helicase, *DDX1*, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K. *J. Biol. Chem.* 277(43), 40403–40409 (2002).
- **Analysis of *DDX1* biochemical activity; *DDX1* associates with heterogeneous nuclear ribonucleoprotein K.**

77. Kanai Y, Dohmae N, Hirokawa N: Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. *Neuron* 43(4), 513–525 (2004).
- **DDX1 localizes to RNA-transporting gradules of neurons.**
78. Jia Z, Barbier L, Stuart H *et al.*: Tumor cell pseudopodial protrusions. Localized signaling domains coordinating cytoskeleton remodeling, cell adhesion, glycolysis, RNA translocation, and protein translation. *J. Biol. Chem.* 280(34), 30564–30573 (2005).
79. Meek SE, Lane WS, Piwnica-Worms H: Comprehensive proteomic analysis of interphase and mitotic 14–3–3-binding proteins. *J. Biol. Chem.* 279(31), 32046–32054 (2004).
80. Pozuelo Rubio M, Geraghty KM, Wong BH *et al.*: 14–3–3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. *Biochem. J.* 379(Pt 2), 395–408 (2004).
81. Fang J, Kubota S, Yang B *et al.*: A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. *Virology* 330(2), 471–480 (2004).
- **Association of DDX1 with HIV-1 Rev; implication for viral replication.**
82. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT: Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. *Cell* 119(3), 381–392 (2004).
83. Fang J, Acheampong E, Dave R *et al.*: The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. *Virology* 336(2), 299–307 (2005).
84. Sunden Y, Semba S, Suzuki T *et al.*: DDX1 promotes proliferation of the JC virus through transactivation of its promoter. *Microbiol. Immunol.* 51(3), 339–347 (2007).
85. Tingting P, Caiyun F, Zhigang Y, Pengyuan Y, Zhenghong Y: Subproteomic analysis of the cellular proteins associated with the 3' untranslated region of the hepatitis C virus genome in human liver cells. *Biochem. Biophys. Res. Commun.* 347(3), 683–691 (2006).
86. Albrecht P, Ansperger-Rescher B, Schuler A *et al.*: Spectrum of gross deletions and insertions in the *RBI* gene in patients with retinoblastoma and association with phenotypic expression. *Hum. Mutat.* 26(5), 437–445 (2005).
87. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. *Lancet* 369(9579), 2106–2120 (2007).
88. Bordeleau ME, Matthews J, Wojnar JM *et al.*: Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. *Proc. Natl Acad. Sci. USA* 102(30), 10460–10465 (2005).
89. Yang HS, Jansen AP, Komar AA *et al.*: The transformation suppressor Pdc4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. *Mol. Cell Biol.* 23(1), 26–37 (2003).
90. Tanner NK, Cordin O, Banroques J, Doere M, Linder P: The Q motif: a newly identified motif in DEAD box helicases may regulate ATP binding and hydrolysis. *Mol. Cell* 11(1), 127–138 (2003).
91. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The CLUSTAL\_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res.* 25(24), 4876–4882 (1997).

## Websites

101. NCBI  
www.ncbi.nlm.nih.gov
102. UniGene  
www.ncbi.nlm.nih.gov/UniGene
103. FlyBase: A Database of *Drosophila* Genes and Genomes  
http://flybase.bio.indiana.edu/

## Affiliations

- *Roseline Godbout*  
Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada  
Tél.: +1 780 432 8901;  
Fax: +1 780 432 8892;  
roseline@cancerboard.ab.ca
- *Lei Li*  
University of Alberta & Cross Cancer Institute, Department of Oncology, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada  
Tél.: +1 780 432 8916;  
Fax: +1 780 432 8892;  
leil@ualberta.ca
- *Rong-Zong Liu*  
University of Alberta & Cross Cancer Institute, Department of Oncology, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada  
Tél.: +1 780 432 8916;  
Fax: +1 780 432 8892;  
rongzong@ualberta.ca
- *Ken Roy*  
University of Alberta & Cross Cancer Institute, Department of Oncology, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada  
Tél.: +1 780 432 8916;  
Fax: +1 780 432 8892;  
royk@dal.ca